Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

Fig. 4

The correlation between the efficacy of Zt/g4-DM1 and the number of RON receptors expressed by cancer cells. The IC50 values for cell viability and cell death were calculated using the GraphPad Prism 6 software and then plotted with individual BC and NSCLC cell lines expressing different levels of RON. Colon cancer DLD-1 cells expressing low levels of RON [25] also were included for comparison. The cell surface RON numbers per cell are: DLD-1, 4480; MDA-MB-231, ~8185; H228, 10,207; DU4475, 14,841; H358, 15,286; and T-47D, 15,756 RON receptors per cell. The IC50 values at or less than 5 μg/ml of Zt/g4-DM1 were used as the effective dose to determine the RON receptor number required to reach the IC95 value. Results shown here are from one of three experiments with similar results

Back to article page
\